Current Alzheimer research最新文献

{"title":"Correlations between Cerebrospinal Fluid Biomarkers and Gray Matter Atrophy in Alzheimer's and Behavioural Variant Frontotemporal Dementia.","authors":"Gaetano Scianatico, Valerio Manippa, Domenico Zaca, Jorge Jovicich, Benedetta Tafuri, Davide Rivolta, Giancarlo Logroscino","doi":"10.2174/0115672050330903240919074725","DOIUrl":"10.2174/0115672050330903240919074725","url":null,"abstract":"<p><strong>Introduction: </strong>Distinguishing between frontotemporal dementia (FTD) and Alzheimer's disease (AD) in their early stages remains a significant clinical challenge. Cerebrospinal fluid (CSF) biomarkers (total Tau, phosphorylated Tau, and beta-amyloid) are promising candidates for identifying early differences between these conditions. This study investigates the relationship between grey matter density and CSF markers in the behavioural variant of frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).</p><p><strong>Method: </strong>CSF and 3D T1-weighted magnetic resonance (MR) images were acquired from 14 bvFTD patients, 15 AD patients, and 13 cognitively normal (CN) matched subjects. The CSF markers and their relative ratios (total Tau/beta-amyloid, phosphorylated Tau/beta-amyloid) were compared across the three groups. Voxel-based morphometry (VBM) was performed to characterize the anatomical changes in bvFTD and AD patients compared to CN subjects. Grey matter density maps were obtained by automatic segmentation of 3.0 Tesla 3D T1-Weighted MR Images, and their correlation with CSF markers and relative ratios was investigated.</p><p><strong>Results: </strong>Results demonstrated that, as compared to CN subjects, AD patients are characterised by higher CSF total Tau levels and lower beta-amyloid levels; however, beta-amyloid and relative ratios discriminated AD from bvFTD. In addition, AD and bvFTD patients showed different patterns of atrophy, with AD exhibiting more central (temporal areas) and bvFTD more anterior (frontal areas) atrophy. A correlation was found between grey matter density maps and CSF marker concentrations in the AD group, with total Tau and phosphorylated Tau levels showing a high association with low grey matter density in the left superior temporal gyrus.</p><p><strong>Conclusion: </strong>Overall, while bvFTD lacks a CSF marker profile, CSF beta-amyloid levels are useful for differentiating AD from bvFTD. Furthermore, MR structural imaging can contribute significantly to distinguishing between the two pathologies.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"371-383"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"User Experience in Virtual Reality (VR) Applications for Elderly People with Cognitive Impairment and Dementia: A Scoping Review.","authors":"Jorge Buele, Fatima Aviles-Castillo, Guillermo Palacios-Navarro","doi":"10.2174/0115672050367594250206103806","DOIUrl":"10.2174/0115672050367594250206103806","url":null,"abstract":"<p><strong>Background: </strong>In recent years, Virtual Reality (VR) has emerged as a promising tool to improve the well-being and functional capabilities of older adults. Although VR applications have shown positive results, their impact on user experience and therapeutic outcomes still needs to be evaluated.</p><p><strong>Objective: </strong>This scoping review aims to analyze existing studies on VR use in older adults with neurodegenerative disorders, focusing on the factors that influence usability, satisfaction, and immersion, as well as the effects on emotional and cognitive well-being.</p><p><strong>Materials and methods: </strong>Empirical studies in English were included on VR applications applied to older adults with cognitive impairment without study design restrictions. The search was conducted in IEEE Xplore, PubMed, Scopus, and Web of Science, identifying a total of 650 initial results. After screening, 14 studies met the inclusion criteria.</p><p><strong>Results: </strong>Immersive VR tends to generate a greater sense of presence, which contributes to improving emotional well-being and reducing neuropsychiatric symptoms, such as apathy and depression. However, its impact on cognitive functions, including memory and executive skills, varied depending on the level of immersion and participant characteristics. Despite these positive findings, significant heterogeneity was evident in study designs, measurement instruments, and user experience indicators.</p><p><strong>Conclusion: </strong>Virtual environments have great potential as a therapeutic tool for older adults, but their success depends on the personalization of applications and the adaptation of technology to the specific needs of this population. Future research should focus on developing standardized protocols, incorporating adaptive technologies such as artificial intelligence, and evaluating the longterm effects of VR to maximize its benefits and minimize its risks. This review was registered in Open Science Framework (OSF).</p><p><strong>Registration number: </strong>10.17605/OSF.IO/PNU36.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"765-778"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Memory in Mobile: Using Smartphone-Based Calendars to Rehabilitate Prospective Memory in Patients with Alzheimer's Disease.","authors":"Mohamad El Haj, Karim Gallouj, Pascal Antoine, Guillaume Chapelet","doi":"10.2174/0115672050369534250127104933","DOIUrl":"10.2174/0115672050369534250127104933","url":null,"abstract":"<p><strong>Introduction: </strong>The rapid growth of mobile phone use and internet access among older adults can provide valuable opportunities for clinicians and researchers to incorporate these technologies into the memory rehabilitation of patients with Alzheimer's disease (AD). Building on this opportunity, previous research has used smartphone calendar applications to cue prospective memory in patients with AD. However, in these studies, the calendar has been programmed to send cues only about the time of prospective events.</p><p><strong>Methods: </strong>We investigated the benefits of the smartphone calendar applications sending notifications about both the time and location of the prospective events. We recruited two groups. In the first group (time-and-location-cued group), we configured smartphone-based calendars to send notifications about the time and location of prospective events, while in the second group (time-cued group), we configured smartphone-based calendars to send notifications only about the time of prospective events. In both groups, we invited patients to attend three prospective events per week during a three-week period.</p><p><strong>Results: </strong>The results demonstrated fewer omissions in the time- and location-cued group than in the time-cued group.</p><p><strong>Conclusion: </strong>Providing patients with AD with several contextual cues through smartphone-based calendars may result in better prospective performance than providing them with only one contextual cue.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"755-763"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic Stroke.","authors":"Daniel P Radin, Sheng Zhong, Rok Cerne, Mohammed Shoaib, Jodi L Smith, Jeffrey Witkin, Arnold Lippa","doi":"10.2174/0115672050365821250127055828","DOIUrl":"10.2174/0115672050365821250127055828","url":null,"abstract":"<p><strong>Introduction: </strong>For over a decade, AMPA receptor allosteric potentiators (AMPAkines) have shown significant effectiveness in multiple preclinical studies related to neurodegenerative and psychiatric disorders underpinned by deficient excitatory synaptic activity. Despite promising preclinical evidence, the clinical translation of AMPAkines has been slow due to the propensity of some of these compounds to produce seizures at or around therapeutic doses.</p><p><strong>Materials and methods: </strong>The preclinical activity of the AMPAkine CX1837 is disclosed in the current work.</p><p><strong>Results: </strong>CX1837 enhanced synaptic transmission in hippocampal slices in vitro and dose-dependently enhanced long-term potentiation, which is believed to control memory consolidation. CX1837 boosted performance in cognition tests, such as the novel object recognition test and the win-shift radial arm maze. CX1837 also increased attentional functioning in the 5-choice serial reaction time task in rats. CX1837 produced positive preclinical effects at 0.01-1.0 mg/kg dose and elicited epileptic effects at 10 mg/kg dose.</p><p><strong>Discussion: </strong>CX1837 has one of the largest safety margins to date in preclinical studies. Low doses of CX1837, which produce acute increases in cognition, may potentially increase neurotrophins when given chronically. This could slow the progression of Alzheimer's disease and reverse deficits secondary to ischemic stroke.</p><p><strong>Conclusion: </strong>Together, our findings highlight CX1837 as a potential candidate for clinical development in order to treat multiple neurodegenerative and psychiatric disorders.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"745-754"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apathy Associated with Alzheimer's Disease.","authors":"Dan Wu, Bo Zhang, Yajuan Chang, Shuming Huang","doi":"10.2174/0115672050350970241216072400","DOIUrl":"10.2174/0115672050350970241216072400","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Apathy is a multidimensional and complex disease that is the primary neuropsychiatric symptom among those diagnosed with Alzheimer's disease (AD). Yet, apathy in AD is sometimes underestimated.</p><p><strong>Methods: </strong>A systematic literature review was conducted using databases such as PubMed, Scopus, and Web of Science. The search utilized specific keywords related to apathy and Alzheimer's disease (e.g., \"apathy,\" \"Alzheimer's disease,\" \"neuropsychiatric symptoms,\" \"front-striatal circuitry\"). The studies were selected based on pre-defined criteria, including publication date (within the last 10 years), peer-reviewed status, and relevance to neurobiological, neurochemical, and behavioral aspects of apathy in AD. The articles were screened through title and abstract reviews, followed by full-text evaluations to ensure they met the inclusion criteria, such as relevance to apathy in Alzheimer's patients, study design rigor, and methodological quality.</p><p><strong>Results: </strong>Some research on the behavioral and neurobiological characteristics of apathy in AD points to the role of the front-striatal circuitry, particularly the anterior cingulate cortex (ACC). In addition, we reviewed the neurochemical, neuropsychological, and neuropathological characteristics believed to be associated with apathy symptoms.</p><p><strong>Conclusion: </strong>The findings indicate that understanding the intricate neurobiological underpinnings of apathy in AD is crucial for developing targeted interventions. Our analysis suggests that a multimodal approach, incorporating both pharmacological and personalized non-pharmacological strategies, could enhance therapeutic efficacy and improve patient outcomes. This highlights the need for future research to explore these combined treatment modalities and their potential to alleviate apathy in AD patients.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"527-537"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant Soup Formulations Show Cholinesterase Inhibition Potential in the Prevention of Alzheimer's Disease.","authors":"Dorota Gajowniczek-Ałasa, Dominik Szwajgier, Ewa Baranowska-Wójcik","doi":"10.2174/0115672050306101240321050146","DOIUrl":"10.2174/0115672050306101240321050146","url":null,"abstract":"<p><strong>Background: </strong>As the cholinesterase theory is a prominent hypothesis underlying our current understanding of Alzheimer's disease (AD), the goal of this study was to compose functional vegan lunchtime soups with potential health benefits in the prevention of AD (in the context of cholinesterase inhibition).</p><p><strong>Materials and methods: </strong>The potential of 36 edible plant raw materials in terms of acetyl- and butyrylcholinesterase inhibition was investigated using a 96-well microplate reader. The most promising ingredients were combined to obtain 18 palatable vegetable soup recipes with 6 dominant flavor, appearance, and aroma variants. To shortlist candidates for in-depth analysis and potential consideration in industrial production, our team performed a sensory analysis of the soups.</p><p><strong>Results: </strong>The white boletus soup exhibited the highest potential for cholinesterase inhibition, further bolstered by the inclusion of other ingredients known for their elevated capacity to inhibit both AChE and BChE. Ingredients such as blackthorn (<i>Prunus spinosa</i>), garlic, and white potato contributed significantly to this inhibitory effect (nearly 100% of AChE inhibition). Notably, intriguing results were also observed for asparagus soup, despite the fact that the inhibitory potential of asparagus itself is negligible compared to other raw materials. The success of the asparagus soup lies in the meticulous selection of various ingredients, each contributing to its overall effectiveness. It was observed that mushroom soups scored the highest in this respect, while the team members' response to nettle soup was the least favorable.</p><p><strong>Conclusion: </strong>The outcomes of our study should serve as a catalyst for further exploration of this important research domain. Our current research focuses on deeper insights into the potential of comprehensive meal options. Furthermore, the synergy/antagonism/non-interaction between respective soup ingredients as well as elements of individual soups' chemical composition is a very interesting topic currently under our intensive scientific investigation.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"81-89"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks.","authors":"Zuber Khan, Sidharth Mehan, Mohd Anas Saifi, Ghanshyam Das Gupta, Acharan S Narula, Reni Kalfin","doi":"10.2174/0115672050289946240223050737","DOIUrl":"10.2174/0115672050289946240223050737","url":null,"abstract":"<p><p>Dementia, an international health issue distinguished by the impairment of daily functioning due to cognitive decline, currently affects more than 55 million people worldwide, with the majority residing in low-income and middle-income countries. Globally, dementia entails significant economic burdens in 2019, amounting to a cost of 1.3 trillion US dollars. Informal caregivers devote considerable hours to providing care for those affected. Dementia imposes a greater caregiving and disability-adjusted life-year burden on women. A recent study has established a correlation between prolonged Proton Pump Inhibitor (PPI) usage and dementia, in addition to other neurodegenerative conditions. PPIs are frequently prescribed to treat peptic ulcers and GERD (gastroesophageal reflux disease) by decreasing stomach acid secretion. They alleviate acid-related symptoms through the inhibition of acid-secreting H⁺-K⁺ ATPase. In a number of observational studies, cognitive decline and dementia in the elderly have been linked to the use of PPIs. The precise mechanism underlying this relationship is unknown. These drugs might also alter the pH of brain cells, resulting in the accumulation of amyloid-beta (Aβ) peptides and the development of Alzheimer's disease (AD). Despite the compelling evidence supporting the association of PPIs with dementia, the results of studies remain inconsistent. The absence of a correlation between PPI use and cognitive decline in some studies emphasizes the need for additional research. Chronic PPI use can conceal underlying conditions, including cancer, celiac disease, vitamin B12 deficiency, and renal injury, highlighting dementia risk and the need for further investigations on cognitive health.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"739-757"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Related Differences in the Association between Life's Essential 8 and Cognition in Cognitively Normal Adults: The CABLE Study.","authors":"Lian Tang, Ling-Zhi Ma, Sun Cheng-Kun, Rong Guo, Lan Tan, Meng-Shan Tan","doi":"10.2174/0115672050349431241014064036","DOIUrl":"10.2174/0115672050349431241014064036","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the relationship between Life's Essential 8 (LE8), a recently updated lifestyle-related health factor, and cognition across multiple life stages.</p><p><strong>Methods: </strong>We enrolled 1098 cognitively normal participants from the Chinese Alzheimer's Biomarker and Lifestyle (CABLE) study. We investigated the interactions between age and LE8 on cognition. Multiple linear regression models were utilized to explore the relationship between the LE8 total scores and its two subscales scores with cognition in the total sample, as well as in the mid-age (≤65 years) and the late-age (>65 years) subgroups. In addition, mediation analyses were performed to explore the biologically plausible pathways between LE8 and cognition.</p><p><strong>Results: </strong>There was a significant interaction effect between age and LE8 total scores on MOCA score (P = 0.030). The mid-age subgroup showed a positive correlation between LE8 total scores and CM-MMSE (β = 0.110, P = 0.005) and MOCA (β = 0.112, P = 0.005) scores. However, no significant associations were found in the late-age subgroup. In the mid-age subgroup, CSF p-tau partially mediated the relationship between LE8 total scores and its two subscales and cognition, with a mediation proportion ranging from 6% to 12%.</p><p><strong>Conclusion: </strong>Our findings revealed that the association of the LE8 total scores with MOCA and CM-MMSE scores were significant in mid-age adults rather than late-age adults, indicating that the association might be age-specific and emphasizing the importance of lifestyle interventions in mid-life.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"411-422"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Updates on Alzheimer's Disease: Pathogenesis, Pathophysiology, Molecular Approaches and Natural Bioactive Compounds Used in Contemporary Time to Alleviate Disease.","authors":"Arun Kumar Mishra, Alankar Srivastava, Varsha Raj, Vipin Saini, Gyas Khan, Harpreet Singh, Amrita Mishra, Sarvesh Paliwal","doi":"10.2174/0115672050361294241211071813","DOIUrl":"10.2174/0115672050361294241211071813","url":null,"abstract":"<p><p>Alzheimer's disease (AD), characterised by gradual memory loss and neurodegeneration, is an important risk to global health. Despite the recent advances in the field of neuroscience, the complex biological mechanisms underlying the aetiology and pathology of AD have not been elucidated yet. The development of amyloid-beta plaques, hyperphosphorylation of tau protein, oxidative stress, and neuroinflammation have been identified as important components. The genesis of AD has been illuminated by advances in molecular techniques, which have shown the contributions of environmental, genetic, and epigenetic variables. Ongoing research is focused on the potential of bioactive compounds as therapeutic agents. Quercetin, epigallocatechin gallate, huperzine A, ginsenosides, omega-3 fatty acids, vitamin E, zinc, bacosides from brahmi, and withanolide A from ashwagandha are among the compounds that have demonstrated encouraging effects in modifying disease pathways. These bioactive substances demonstrate their potential for symptomatic relief by providing neuroprotective, antioxidant, anti-inflammatory, and cognitive-enhancing properties. The present review presents the recent findings on AD pathogenesis, molecular mechanisms, and the impact of natural compounds, offering a comprehensive perspective on current and emerging strategies for managing this debilitating condition.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"538-556"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetyl-L-Carnitine Aids in Preservation of Cholinergic Neurons and Memory in the <i>Drosophila melanogaster</i> Model of Alzheimer's Disease.","authors":"Olga I Bolshakova, Alexandra D Slobodina, Elizaveta E Slepneva, Svetlana V Sarantseva","doi":"10.2174/0115672050347906241203075930","DOIUrl":"10.2174/0115672050347906241203075930","url":null,"abstract":"<p><strong>Background: </strong>The lack of effective therapy for the treatment of Alzheimer's disease demands both the search for new drugs and the reconsideration of already known substances currently used in other areas of medicine. <i>Drosophila melanogaster</i> offers the potential to model features of Alzheimer's disease, study disease mechanisms, and conduct drug screening.</p><p><strong>Objectives: </strong>The purpose of this work was to analyze the neuroprotective properties of the drug \"carnicetine\", which is an acetylated form of the natural low molecular weight compound L-carnitine. The drug is able to cross the blood-brain barrier and is currently used as a means of improving cellular metabolism.</p><p><strong>Methods: </strong>Using tissue-specific drivers, direct expression of amyloid beta peptide (42 amino acids) was exhibited in certain groups of neurons in the <i>Drosophila melanogaster</i> brain, namely in dopaminergic and cholinergic neurons. The effect of acetyl-L-carnitine (carnicetine) on the death of these neurons and the memory of flies was analyzed.</p><p><strong>Results: </strong>The expression of amyloid beta peptide in dopaminergic or cholinergic neurons resulted in neurodegeneration of cholinergic neurons in the <i>Drosophila</i> brain and memory impairment. The use of carnicetine added to animal food made it possible to treat these disorders. At the same time, no effect on dopaminergic neurons was noted.</p><p><strong>Conclusion: </strong>The data obtained confirmed the neuroprotective properties of the drug under study, demonstrating its participation in the restoration of the cholinergic system and the feasibility of using carnicetine for the treatment of Alzheimer's disease.</p>","PeriodicalId":94309,"journal":{"name":"Current Alzheimer research","volume":" ","pages":"557-565"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}